Navigation Links
Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
Date:2/15/2011

IRVINE, Calif., Feb. 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the presentation of the initial clinical results from the PEVAR Trial at the 2011 iCON (International Congress of Endovascular Specialists) annual meeting in Scottsdale, Arizona. Among 33 patients enrolled in the Roll-In phase of the trial, technical success rates of 97% (access) and 100% (endovascular repair) have been achieved, with no major adverse events observed. Patients were discharged from the hospital at an average of 1.4 days following the procedure.

Participating investigator and presenter Zvonimir Krajcer, MD (Director, Peripheral Vascular Disease Service, St. Luke's Episcopal Hospital at the Texas Heart Institute, Houston, TX) commented, "In our multidisciplinary practice, a totally percutaneous approach to endovascular repair with the IntuiTrak System and Abbott's Prostar XL closure device has demonstrated substantial patient benefits as we recently reported in the Journal of Cardiovascular Surgery.   These initial outcomes in the PEVAR Trial roll-in phase are consistent with the published single center data, and have served to support initiation of the randomized phase of the trial. We are very pleased with the initial results, and look forward to completion of the randomized trial very soon."

The PEVAR Trial is the first multicenter, prospective, randomized trial of totally percutaneous endovascular repair of abdominal aortic aneurysm and is being conducted at 20 centers in the United States under an Investigational Device Exemption approved by the U.S. Food and Drug Administration.

John McDermott, President and Chief Executive Officer said, "We applaud the PEVAR Trial investigators for their diligence and dedication to the trial, and commitment to improving patient outcomes. We
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
6. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
7. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
8. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
9. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
10. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
11. Endologix Reports 30% Third Quarter 2010 Revenue Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- ScriptPro has been certified by ... Common Security Framework (CSF). According to Russ ... "We appreciate this rigorous, top-to-bottom audit. Security-minded customers ... certification signifies. Our business partners need to know ... CERTIFICATION PROCESS: ScriptPro,s internal security processes and controls ...
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... 13 An 80-year-old lung cancer patient has become ... using a new linear accelerator that can deliver precise ... Center carried out the treatment last week, becoming only ... using TrueBeam™ from Varian Medical Systems (NYSE: VAR). ...
... CANTON, Ohio, Sept. 13 AultCare has been ... in partnership with Cardiocom, released a white paper ... The paper describes the structure of ... and patient. Improved patient self-management has resulted in ...
Cached Medicine Technology:Leading Dutch Cancer Center Commences Treatments Using New TrueBeam from Varian Medical Systems 2Leading Dutch Cancer Center Commences Treatments Using New TrueBeam from Varian Medical Systems 3AultCare/Cardiocom® White Paper Shows Telehealth Services Reduce ER Visits and Inpatient Stays for Patients 2
(Date:8/21/2014)... The world wound care market is expected to ... USD 18.3 billion by 2019, posting a CAGR of ... growth include governments’ contribution to the development of wound ... ageing population. However, the growth could be restrained by ... America leads the global wound care market, with the ...
(Date:8/21/2014)... August 21, 2014 The second ... by Boston Scientific has begun in Massachusetts state ... trial. The Rottenstein Law Group LLP, a national ... claims of harm stemming from the implantation of ... for compensation for injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ ...
(Date:8/21/2014)... 2014 Lauren Collura, a mother of two ... to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and two ... beachfront house in Lavallette beginning this Saturday. , This ... sweepstakes. Last year, Horizon Blue Cross Blue Shield of New ... Sandy and decided to make it a new summer tradition. ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... this year's conference will focus on the Future ... for research, innovation and commercialization. , With the ... SALSS combines the worlds' of business and science. ... widely recognized Summit, gathering a diverse community with ...
(Date:8/21/2014)... (HealthDay News) -- In a new review of seafood ... eating tuna due to concerns about mercury exposure. ... only to shrimp as the most commonly eaten seafood ... avoid all tuna," Jean Halloran, director of food policy ... Reports, said in a news release from the group. ...
Breaking Medicine News(10 mins):Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2
... get boosted by a 'super' form of an enzyme called Akt1. ... cells. These cells are also referred to as the main switch ... to attack a tumor. This was divulged in a report that ... the journal Nature Biotechnology. Researchers from Baylor College of Medicine conducted ...
... appears to be something of a great divide in terms ... Britons and their health conscious watch –what –you -eat// fellow ... worried about rocketing obesity figures that cost the NHS around ... new plan.,This involves trusts funded by them to get people ...
... magnet, that is currently used in many commercial gadgets ... implanted heart devices,// like the pacemaker, with fatal consequences. ... magnets were introduced into the market recently and are ... more familiar, dull grey iron magnets. Since the cost ...
... tennis elbow ask them to alter the grip size of ... the muscle firing patterns in the forearm demonstrates that grip ... ,Researchers apparently have "gotten a grip" on the relationship ... of the grip on the racket a player uses. ...
... who take breaks in antiretroviral (ARV) drug treatment face greater ... take their medicine regularly, according to a new study in ... end a long debate on the value of 'drug holidays', ... a popular strategy in the war against HIV and AIDS ...
... symptoms of post-traumatic stress disorder, is no more effective than ... the San Francisco VA Medical Center. ,“There was ... effects,” says lead author Thomas Neylan, MD, medical director of ... PTSD should probably stay away from this drug and others ...
Cached Medicine News:Health News:Enzyme to Boost Effect of Tumor Vaccine 2Health News:Magnets in Commercial Products may Cause a Fatal Attraction 2Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 2Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 3Health News:'Drug Holidays' Increases Death Risk in HIV Patients 2Health News:Common PTSD Drug is No More Effective Than Placebo 2
... AST (GOT) powder reagent once reconstituted offers ... liquid stability to help maximize laboratory productivity, ... turnaround time. The patented technology of the ... long shelf life and stability once reconstituted ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: